Transcranial Magnetic Stimulation Guided by Personalized Brain Functional Sectors (pBFS) for Language Deficit Comorbid in Autism Spectrum Disorder Child: a Multi-center, Randomized, Sham-controlled Trial
The aim of this trial is to evaluate the efficacy and safety of precision neuromodulation in improving language ability in children with autism spectrum disorder (ASD) who also have language development delay. The neuromodulation will be delivered using the accelerated intermittent theta burst stimulation (aiTBS) protocol, targeting the language network in the left superior frontal gyrus (SFG), guided by personalized Brain Functional Sector (pBFS) technology.
• Professionally diagnosed with ASD per DSM - 5 criteria.
• Aged 3 - 6.5 years, either gender.
• ADOS-2 results meet ASD standard cut - off.
• SCQ score: ≥15 (age ≥ 4 years) or ≥11 (age \< 4 years).
• Co-existing language disorder not explaining ASD symptoms. No organic speech organ lesions. CNBS-R2016 and CLAS-TP language-related equivalent age \> 18 months; any CLAS-TP dimension score \< 6.
• Mandarin is the daily communication language.
• May have intellectual/global developmental delay not explaining ASD symptoms.
• Guardians volunteer, can cooperate in treatment and sign informed consent.